High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation

Ruoyu Huang1,2,3,4,5 | Yanwei Liu1,2,3,4,5 | Kuanyu Wang1,2,3,4,5 | Zheng Wang1,2,3,4,5 | Chuanbao Zhang1,2,3,4,5 | Wei Zhang1,2,3,4,5 | Zheng Zhao1,2,3,4,5 | Guanzhang Li1,2,3,4,5 | Lijie Huang1,2,3,4,5 | Yuanhao Chang1,2,3,4,5 | Fan Zeng1,2,3,4,5 | Tao Jiang1,2,3,4,5 | Huimin Hu1,2,3,4,5

1Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
3Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
4China National Clinical Research Center for Neurological Diseases, Beijing, China
5Chinese Glioma Genome Atlas Network (CGGA), Beijing, China

Abstract

Background: PTPRZ1-MET (ZM) is a critical genetic alteration driving the progression of lower-grade glioma. Glioma patients harboring ZM could benefit from MET inhibitors. According to the remarkable role of ZM as a driver of glioma progression and indicator of MET inhibitor sensitivity, it is necessary to detect this alteration even when it presents in glioma with relatively fewer copies.

Methods: Herein, we proposed that ZM could be detected with a high-sensitive method of reverse transcriptase PCR with 50 amplification cycles. Via this newly proposed detection method, we depicted the incidence preference of ZM fusion in a cohort of 485 glioma patients. To further explore the oncogenic nature of ZM, we predicated the protein structure alteration of MET kinase brought by its fusion partner.

Results: The incidence of ZM fusions was much higher than previous report. ZM fusions exhibited a striking preference in lower-grade glioma and secondary glioblastoma. By contrast, none of patients with primary glioblastoma was detected harboring ZM fusion. In each of the four variants of ZM, the fusion partner segment of MET contained a remarkable coiled-coil motif. In glioma cells expressing ZM, MET kinase could be activated in a ligand-independent manner, which might be contributed by the special coiled-coil structure brought by the fusion partner. Corresponding to the 3D structural analysis and cell line experiment, the ZM positive clinical specimens showed hyperactivations of MET signaling.

Conclusions: ZM fusions are critical drivers of glioma progression and effective target of MET inhibitor. Early detection could be performed with a high-sensitive method of reverse transcriptase PCR. The hyperactivations of MET signaling driving glioma
progression might be contributed by a ligand-independent activation enabled by the protein structure modification of extracellular domain of MET in ZM fusions.

**KEYWORDS**
coiled-coil structure, glioma progression, MET inhibitor, receptor tyrosine kinase

1 | INTRODUCTION

Gliomas including lower-grade glioma (LGG, World Health Organization grades II and III) and glioblastoma (GBM, WHO IV) are highly fatal primary intracranial tumor. Although patients of LGGs live longer with symptoms of less severity, their cancers will progress into secondary glioblastoma (sGBM) invariably. Unlike that the static states of LGG keep for 5–10 years, sGBM progresses rapidly and the median overall survival of patients with sGBM is only 31 months even after surgery and adjuvant chemoradiotherapy. With paired LGG and sGBM samples, several longitudinal studies proposed the roles of PI3 K/Akt/mTOR pathway, RB pathway, cell-cycle regulations, and DNA methylation reprogramming in driving or at least contributing to glioma progression. In the recent research of our laboratory, we illustrated the driver role of a fusion gene, PTPRZ1-MET (ZM), in the progression of LGG to sGBM. We had known that ZM happens in ~14% of cases of sGBM with significantly worse prognosis and causes activation of MET signaling. The abnormal MET activation led to glioma progression and indicated MET-inhibition sensitivity. These findings guided to a clinical trial of treatment of patients with high-grade glioma (WHO III & IV) with novel MET-targeted compound. Tumor shrinkage and symptom relief were observed after treatment. The trial of clinical phase II is ongoing.

As ZM is a driver of glioma progression and an indicator of MET-inhibition sensitivity, it is meaningful to detect ZM fusions even when they are still present in tumors with relative fewer copies. Herein, we report a high-sensitive and low-cost method to detect ZM fusions in glioma tissues. This method could be used as the “gold standard” of ZM positive (ZM+) glioma diagnosis as the fusion point of PTPRZ1 and MET could be confirmed via Sanger sequencing included in this method. Despite the critical roles of ZM fusions in LGG progression that have been proposed, the intrinsic mechanism of MET activation launched by ZM has not been explored. With 3D protein structure prediction, we found that the fusion partner fragment added to MET kinase in ZM fusion protein contains a coiled-coil structure which might contribute to the ligand-independent MET activation.

2 | MATERIALS AND METHODS

2.1 | Human tissues and dataset

Glioma tissues and the patients’ follow-up information (diagnosis, gender, age, WHO grade, PFS, and OS) were obtained from the Chinese Glioma Genome Atlas (CGGA) dataset. Patients treated at Beijing Tiantan Hospital, Sanbo Hospital in Beijing, Harbin Medical University and China Medical University were included in this study. Written consent was obtained from all patients. The glioma tissues were snap-frozen in liquid nitrogen immediately after surgical resection and preserved in liquid nitrogen. Only samples with >80% tumor cells were enrolled for analysis. The establishment and management of our CGGA databank has been introduced in our previous publications. Information of the critical histology and molecular features of the tumors in this study was derived from CGGA dataset (http://www.cgga.org.cn/).

The peripheral blood from patients harboring ZM+ or ZM negative (ZM−) glioma used in this study was collected from dorsalis pedis artery. Two milliliters of whole blood were collected from each patient.

All the processes of tissues and information collection were approved by the Institutional Review Boards of Beijing Tiantan Hospital (No. KY2014-002-02) and were conducted in accordance with the principles expressed in the Declaration of Helsinki.

2.2 | Detection ZM fusions in glioma tissues and peripheral blood

Glioma tissue RNA was abstracted using the RNaprep pure Tissue Kit (Tiangen Biotech) followed by cDNA synthesis (RevertAid RT Kit, Thermo Fisher Scientific).

RNA concentration and quality were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Only RNA with A260/A280 values >1.8 and <2.0 were adopted in following processes. The integrity of total RNA was evaluated by agarose gel electrophoresis after the RNA samples were ten times diluted. Only if the bands of 28S rRNA and 18S rRNA were both bright and clear, and the bright intensity of 28S rRNA: 18S rRNA was about 2:1, the RNA was identified as qualified. Complementary DNA was synthesized from 1 µg of qualified total RNA using the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen).

RT-PCR were performed using 1 µl of cDNA. The PCR program included denaturing at 95°C (30 s), annealing at 58°C (30 s), and extension at 72°C (30 s). Primers flanking the fusion points of ZM (forward: 5′-CCGTCTGGAAATGCAGAATCCTAAA-3′ reverse: 5′-CAGGCCCAAGTCTTGATACACGCAA-3′) were used to clone the sequences crossing the fusion points with DNA polymerase (GoTaq, Promega). The primers were designed based on the PTPRZ1 and MET segments that are common to all the four ZM fusion variants. All the four ZM fusion variants could be specifically amplified using this pair.
of primers, and amplification products were of different sizes (ZM variant 1: 337 bp; ZM variant 2: 403 bp; ZM variant 3: 583 bp; ZM variant 4: 1207 bp). In every examination, a negative control test to avoid cross-contamination or false positive was performed simultaneously with nuclease-free water, and a positive control test to avoid false negative was performed with an already-known ZM+ cDNA.

After electrophoresis, the amplification product bands were purified and submitted for Sanger sequencing. The sequencing reads were aligned to the known ZM fusion sequences to determine whether ZM fusions were present in the given glioma specimen and which variant it was.

RNA of whole blood was abstracted with RNAprep Pure Hi-Blood Kit (Tiangen Biotech). The following reverse transcription step and ZM fusions examination step were as the corresponding steps in ZM detection of glioma tissues mentioned above.

Quantification of the bands’ gray intensity was performed with the software of ImageJ following phase inversion.

### 2.3 Cell culture

Glioma cell line U87 MG was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose. The DMEM culture medium was supplemented with 10% fetal bovine serum (FBS, HyClone), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). The cell line was cultured at 37°C in a humidified atmosphere of 5% CO₂.

### 2.4 Construction of adenoviral vectors encoding ZM fusions and transduction ZM variants into glioma cell line

ZM variant 1 and ZM variant 2 coding sequences were separately cloned from ZM+ gliomas tissues and transferred into a His6-tagged pShuttle-CMV vector. The sequences were then individually recombined into the pADxsi vector. Insertion of the right sequences was confirmed with restriction enzyme digestion and sequencing. The recombinant plasmid was subsequently linearized by restriction enzyme digestion and transfected into HEK293A cells with Lipofectamine2000 (Thermo Fisher Scientific) for the generation of adenoviral vectors. The collected adenoviral vector was aliquoted and stored at ~80°C before use. U87 MG cells were treated in the medium containing an appropriate titer of the adenoviral vector for 6 h before medium change. ZM fusions expression in the cell line was confirmed by RT-PCR.

### 2.5 Western blotting

Glioma tissue or U87 MG cells were lysed with RIPA buffer (Cell Signaling Technology) supplemented with protease inhibitor (Solarbio biotech). Protein concentration was evaluated using Coomassie Brilliant Blue on a microplate spectrophotometer (Infinite M200 PRO, Tecan). Equal amounts of tissue or cell total protein (30 μg) were loaded on a 10% SDS/PAGE gel, transferred to a PVDF membrane (Merck Millipore), and detected using an ECL Western Blotting Detection System (Bio-Rad). The information of the primary antibodies used in the current study was in accordance with the corresponding antibody information in the Star Methods in our previous publication.7

β-Tubulin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the loading control. Goat anti-rabbit IgG-HRP or goat anti-mouse IgG-HRP was used as secondary antibody. The gray intensity of the bands was quantified by ImageJ software.

### 2.6 Protein secondary structure prediction

The sequence of the first 200 (the number of predicated amino acids is limited in the algorithm) amino acids added to MET in ZM variant 4 (exon8 of PTPRZ1 binding to exon2 of MET) was submitted to QUARK online service server (https://zhanglab.ccmb.med.umich.edu/QUARK2/). In the returned 3D structure, the additional segments to MET in the other three variants were highlighted in blue with PyMOL (2.3).

### 2.7 Data analysis and graphing

Survival analysis of patients was performed using GraphPad Prism 7 software. Log-rank test was used to test the significance of difference of overall survival or progression-free survival. Univariate and multivariate COX regression analyses were performed with SPSS 12.0. Statistical graph was obtained using SigmaPlot 14.0. In all statistical analysis, p value<0.05 was considered statistically significant.

### 3 RESULTS

#### 3.1 A high-sensitive and specific detection method of ZM fusions

The copy numbers of ZM fusions in different patients varies. As the driver role of ZM in glioma progression, it is necessary to detect its presence as early as we can.

We designed a method as performing two times of reverse transcriptase PCR (RT-PCR) for each glioma tissue using primers flanking the fusion points. The numbers of amplification cycle in each RT-PCR were separately 30 and 50. The PCR product bands in agarose gel were purified and sequenced using Sanger sequencing and the fusion point of PTPRZ1 and MET were identified to confirm the presence of ZM fusions and which variant the fusion is (Figure 1). In every examination, a negative control test to avoid cross-contamination or false positive and a positive control test to avoid false negative were performed simultaneously.
In this method, RT-PCR of 50 amplification cycles was employed so we could detect ZM fusions when they present with a small number of copies. The number of amplification cycles was much more than that commonly used in PCR. Thus, before we determined the mentioned ZM fusion detection method (PCR- Sequencing), we firstly demonstrated the specificity and robustness of ZM fusions using reverse transcriptase PCR of 50 amplification cycles (Figure 2). In the ideal amplification model, ZM fusion segment should be efficiently produced. Furthermore, as ZM fusions are somatic mutations, it should not be detected in ZM+ glioma tissues or peripheral blood from ZM+ patients, even if the number of amplification cycles was large enough. (Figure 2A). To evaluate this method, we collected peripheral blood specimens from patients harboring ZM or not as control tissue. As expected, RNA extracted from ZM+ glioma tissue produced a remarkable band after RT-PCR, whereas no specific PCR product could be detected with the whole peripheral blood RNA from ZM+ patient (Figure 2B).

Theoretically, quantity of specific PCR product grows exponentially along with numbers of amplification cycles until reaches the plateau phase. To detect early ZM fusions still present with fewer copies, we did a test to separately perform RT-PCR with numbers of amplification cycles as 30, 40, 50, and 60 (Figure 2C). Among ten ZM+ glioma tissues, three tissues (samples noted as “2”, “6”, and “9”) could be identified ZM+ at 30 amplification cycles. Along with increase in amplification cycles numbers from 30 to 50, the quantity of PCR product grew. Until amplification cycle number reached 50, all the ten samples produced specific bands. Nevertheless, PCR product quantity kept stable and not increased markedly at 60 amplification cycles.

Before we finally certified the glioma samples as ZM+, all the PCR product bands on agarose gel were purified and sequenced via Sanger sequencing. The sequencing reads were aligned to the known ZM fusion sequences. The existence and the variant of ZM fusions then was confirmed and clinically reported.

3.2 | The incidence preference of ZM fusions

Using the above-stated diagnosis approach, we examined the incidence of ZM fusions in a cohort consisting of 485 adults with WHO grade II-IV diffuse glioma from different regions in China. ZM fusions occurred more frequently in sGBMs than in grade II and
grade III gliomas (Figure 3A, Pearson chi-squared test, $\chi^2 = 33.657$, $p < 0.001$). As a contrast, none of the primary GBM was found ZM+, which was in accordance with our previous discovery that ZM was a driver of the progression from LGG to sGBM. ZM fusions were more frequent in grade III astrocytomas (AA, 13.9%) and sGBMs (26.7%), whereas only 3.2% of the grade III oligoastrocytomas (AOA) harbored ZM fusions (Figure 3B) suggesting a preference in gliomas with astrocyte origin. The 24 sGBM samples harboring ZM fusions include 4 ZM+ samples involved in our previous study. All other ZM fusions positive specimens were firstly reported here.

Four ZM fusion variants involving four different breakpoints: exon 1, 2, 3, or 8 within PTPRZ1 coding sequence and one common
breakpoint (exon 2) within MET were confirmed. Fusions with exon 1 or 2 of PTPRZ1 fused to exon 2 of MET (Exon1-Exon2 or Exon2-Exon2, respectively) were the most common variants (46.8% and 23.4%, respectively) (Figure 3C). Three of the four variants we found and confirmed through the proposed RT-PCR method, the ZM variant 1, 2, and 4 separately with exon 1, 2, or 8 of PTPRZ1...
fused to exon 2 of MET had been previously reported in pediatric glioblastoma. ZM variant 3 with exon 3 of PTPRZ1 fused to exon 2 of MET was our unique discovery and had not been previously reported.

Based on diagnosis results given by RT-PCR examination, we confirmed that ZM conferred a negative survival effect in sGBM patients. Kaplan-Meier survival analysis demonstrated poor overall survival (OS) for patients with ZM fusion-positive sGBM compared with sGBM patients without ZM fusion (median OS: 239 d vs. 318 d, respectively; \( p = 0.0043 \), log-rank test) (Figure 3D, Table S1). A similar trend was found for progression-free survival (PFS) (median PFS: 116 d vs. 240 d, respectively; \( p = 0.0001 \), log-rank test) (Figure 3E, Table S1). In Univariate and Multivariate Cox regression analyses, ZM fusions exhibited independent prognostic value for glioma patients (Table 1).

The landscape of ZM fusions and the critical histology and molecular features counted in the definition of 2016 WHO classification of glioma revealed the correlations of ZM fusion incidence with the 2016 WHO classification of glioma (Table 1). ZM fusions distributed exclusively in AA and GBM, whereas their distribution did not show specific preference depending on IDH status (Figure 4B, the specimens do not fit into any narrowly defined classifications which were labeled as "NOS" were not counted).

We further investigated the clinical features of sGBM patients harboring ZM fusion or not. The incidence of ZM fusion in younger patients (Age < 40) was higher (36.84% vs. 17.50%) than elder (Age ≥ 40) patients (Figure 5A, Table S2). In the cohort of 55 patients with sGBM progressed from LGGs of WHO II, ZM fusion incidence was 18.18%, whereas in patients who had been initially diagnosed with glioma of WHO III grade before sGBM (N = 15), the incidence of ZM fusion was 33.33% (Figure 5B, Table S2). As epileptic seizure is a component of syndrome of LGG and glioblastoma, we explored the correlation between the occurrence of seizures and ZM fusion incidence. Before surgical resection, the occurrence rate of seizures in patients with ZM+ sGBM was 7.69% (Figure 5C, Table S2); significantly lower than the occurrence rate of seizures in patients with ZM- sGBM (29.55%). After surgical resection, the occurrence rate of seizures in patients with ZM- sGBM was prominently reduced to 12.77%. Meanwhile, none of the patients with ZM+ sGBM had seizures occurred after surgical resection (Figure 5D, Table S2).

3.3 The coiled-coil structures in ZM fusions contribute to ligand-independent MET activation

In previous studies, we had revealed that the abnormal activation of MET signaling caused by ZM fusions was a critical mechanism of driving LGGs progress to sGBM. To further illustrate the mechanism of MET hyperactivation in gliomas harboring ZM fusions, we analyzed the protein structure of the partner fragment of MET (the PTPRZ1 fragment) in PTPRZ1-MET. Via QUARK, an algorithm determining spatial location of every atom in a protein molecule from the amino acid sequence developed by Dong Xu and Yang Zhang, we predicted the 3D structure of the first 200 amino acids (the number of predicted amino acids is limited in the algorithm) added to MET in ZM variant 4 (exon8 of PTPRZ1 binding to exon2 of MET). As ZM variant 4 is the longest PTPRZ1-MET fusion, the additional fragments of PTPRZ1 in all the other three ZM variants are included in these 200 amino acids (Figure 6A). The additional segments to MET in all these four variants contained remarkable coiled-coil motifs (Figure 6B, Figure S1). These characteristic structure of coiled-coil often indicating ligand-independent dimerization and kinase hyperactivation.

To verify whether the ZM fusions could cause a ligand-independent kinase hyperactivation or not. Experiments in vitro were performed in U87 MG cell line with adenoaviral-mediated expression of ZM variant 1 or 2. The results showed that MET signaling activation remained persistent following blockade of HGF with anti-HGF antibodies in FBS-free medium (Figure 6C), suggesting ZM fusions caused MET hyperactivation in a ligand-independent manner. We examined MET signaling activity in seven ZM+ glioma tissue samples, five ZM+ gliomas, and a normal brain tissue. Immunoblotting analyses showed strong phosphorylation of MET and its down-stream signaling including STAT3, ERK, and AKT in ZM+ tumors (Figure 6D, E). Among the ZM+ tumors, CGGA_P24,

| Variables      | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | HR (95% CI)         | \( p \) value         |
| ZM fusion      | 1.663 (1.095–2.526) | 0.017                 |
|                | 23.039 (4.637–114.479) | <0.001                 |
| Age at Diagnosis | 0.711 (0.507–0.997) | 0.048                 |
| Gender         | 0.802 (0.662–1.143) | 0.222                 |
| IDH1 mutation status | 0.656 (0.424–1.016) | 0.059                 |
| MGMT methylation | 1.159 (0.638–2.105) | 0.627                 |
| 1p19q co-deletion | 0.577 (0.282–1.184) | 0.134                 |
| Chemotherapy   | 0.833 (0.583–1.188) | 0.313                 |
CGGA_1685, and CGGA_P5 were diagnosed as ZM fusion positive via the detection method with 50 amplification cycles as above mentioned (Figure 2).

**FIGURE 4**  The correlations of ZM fusion incidence with the 2016 WHO classification of glioma. A, The landscape of ZM fusions and the critical histology and molecular features counted in the definition of 2016 WHO classification of glioma. B, Distribution of ZM fusions in tumors with 2016 WHO classification of glioma. (the specimens do not fit into any narrowly defined classifications which were labeled as “NOS” were not counted). NOS: not otherwise specified.

4 | DISCUSSION

We had previously reported the presence of ZM fusion in glioma.\(^5\) Subsequently, we elaborated that ZM fusions co-occurred with MET-exon-14-skipping, and both two MET alterations promoted glioma progression. Based on these findings, patients with ZM+ high-grade glioma (WHO III and IV) had been enrolled in a clinical trial of blocking malignant progression with a highly selective and BBB-permeable MET kinase inhibitors.\(^7\)

In tumors, the canonical driver genetic alterations could be acquired and seeded very early.\(^{16}\) Since the linear progression model of cancers indicating that cancer progression is closely dependent on accumulation of somatic alterations is one of the most widely accepted theory,\(^{17,18}\) heterogeneity of critical alterations and the resulted distinct subpopulation of cancer cells have been established in early primary tumor.\(^{19,20}\) Considering that ZM fusions are critical drivers of glioma progression and the clonal evolution of ZM fusion copies,
detection of these fusions even if they are present in glioma tissues with few copy numbers is meaningful and will benefit the patients.

However, the feature of fusion genes including two sequences from two totally different genes decides the difficulties of their detection, especially in clinical diagnosis. The antibodies for either of the two fusion partners are not specific enough for the fusion protein, while development of a specialized antibody targeting the fusion point is arduous. Fluorescent in situ hybridization (FISH) has a tedious operating process and the diagnostic results prone to be bias depending on the field of the pathological slices under the microscope. It means that FISH is not an ideal approach to detect ZM fusions as this early seeding genetic alterations might be dispersive in tissue bulk with very fewer copies. Bulk tumor with gene rearrangements might be missed as negative via FISH examination while be identified as positive by qRT-PCR analysis. Besides, the "off-target" hybridization is common because of the high-level of sensitivity of FISH. This defect might exaggerate the incidence of the genomic alterations.

Real-time PCR is a commonly used method to detect clinically meaningful genetic alterations in cancers. However, real-time PCR is not applicable to detect ZM fusions. The quantity capacity of real-time PCR assay is based on the stable amplification efficiency of primers. Whereas, ZM fusions contain four variants of different lengths. The amplification efficiency of the primers is difficult to keep consistent when different ZM fusion variants are detected. For real-time PCR, the optimal PCR product size is between 100 and 150 base pairs. PCR product of such length is not applicable for gel cutting from agarose gel after electrophoresis and the following PCR product purification. As Sanger sequencing and sequence alignment with the known ZM fusion gene sequences is required for ZM detection, the procedure of PCR product purification is needed.

In the current study, we proposed a detection approach containing two times of reverse transcriptase PCR (RT-PCR) with 30 or 50 amplification cycles separately to amplify ZM fusion segments before Sanger sequencing. We proved that the relative larger number of amplification cycles could ensure clearly confirmation of ZM fusions with fewer copies. The subsequent Sanger sequencing of the PCR products and sequence alignment with the known ZM fusion gene sequences would make the fusion point of PTPRZ1 and MET visualized and further confirm the presence of ZM fusions. Moreover, the RT-PCT and Sanger sequencing techniques are low cost.

With the proposed PCR-Sequencing approach, we described the incidence features of ZM fusion genes. The incidence was found higher than our previous reports, in which ZM fusions were detected by RNA-seq and confirmed by RT-PCR. As the repressive effects of MET inhibitor in malignant progression of ZM+ glioma had emerged, the early detection of these alterations will benefit the patients in prevention or early management.

MET signaling activation is dependent on binding of MET kinase with its ligand HGF. The large N-terminal domain of MET (the Sema domain) is necessary for HGF binding and dimerization. In ZM fusion protein, the MET structure remained intact overall, whereas the Sema domain was modified by PTPRZ1 fragment, which might be the cause of ligand-independent phosphorylation of the MET kinase domain.
In classic model of receptor tyrosine kinase (RTK) activation, ligand binds to the extracellular ligand pocket and causes two monomers’ combination in a process termed as dimerization. Such the active signaling brought by ligand would be transduced to intracellular domain. Subsequently, the intracellular kinase domain is auto-phosphorylated, and the growth receptor becomes catalytically active.

The dimerization mechanisms vary in different RTKs. The main mechanisms are the three ones as following: Each RTK monomer binds to a ligand molecule and then dimerizes; two monomers are linked by a single ligand molecule and then dimerizes; or two monomers are originally linked by a disulfide bond in their extracellular region, and after ligand binding, the intracellular domains conformation change and bind each other.

For MET, the extracellular SEMA domain is the key structure for ligand binding and dimerization. In ZM fusions, the fusion partner sections are added to the SEMA domain, suggesting that the modification prone to affect the critical step of ligand binding and dimerization of MET kinase. To verify this hypothesis, we performed in vitro experiments with U87 MG cell line. The results suggested that ZM fusions could cause MET hyperactivation in a ligand-independent manner. As a primary GBM cell line, the use

Figure 6: Coiled-coil structures in ZM contribute to ligand-independent MET activation. A, Diagram that MET is modified by PTPRZ1 fragment adding to SEMA domain. B, The 3D protein structure predicted using QUARK algorithm. The predicted structure of the first 200 amino acids added to MET in ZM variant 4 (exon8 of PTPRZ1 binding to exon2 of MET) is shown in yellow, and the PTPRZ1 segments in ZM variant 1, 2, and 3 are separately highlighted in blue. C, ZM fusion leads to MET hyperactivation in a ligand-independent manner. Following 12 h of serum starvation and HGF blocking with 6 μg/ml of HGF antibody, MET hyperactivation caused by adenoviral vector-mediated transient expression of ZM fusion (variant 1 or 2) in U87 MG cells was not impaired. VE: vector control. D, Immunoblotting shows strong phosphorylation of MET and its down-stream signaling in ZM fusion-positive glioma compared with normal brain tissue (NBT) and ZM-free glioma. CGGA_P24, CGGA_1685, and CGGA_P5 were diagnosed as ZM fusion positive via the detection method with 50 amplification cycles (indicated by asterisk). HMU: ID for patients from Harbin Medical University. E, The gray intensity of the immunoblotting bands in (D). *p < 0.05, **p < 0.01, ns: no statistically significant.
of U87 MG had potential limitation to study the malignant progression from LGG to sGBM. However, considering the lack of low-grade or secondary glioma cell lines, U87 MG cell line was still a reasonable and reliable choice. Besides, as a MET-dependent glioma cell line, U87 MG was widely used in MET signaling pathway-related researches.\(^{32,33}\)

The incidence of ZM fusions in different age of patients with sGBM was distinct. The occurrence rate of seizures was also different in patients depending on whether their tumors harboring ZM fusions or not. This finding suggested that the ZM fusion status may serve as a potential indicator of epileptic seizures and surgical seizure and the detection of ZM fusion could provide a more accurate assessment of personalized treatment in clinic. The above clinical relevance suggested that there is still a long way before fully uncovering the influence of the existence of ZM fusions in glioma progression.

ACKNOWLEDGMENTS
Not applicable.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interests.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

CONSENT TO PARTICIPATE
Informed consent was obtained from all individual participants for CGGA project in this study.

ORCID
Kuanyu Wang https://orcid.org/0000-0002-2825-6011
Wei Zhang https://orcid.org/0000-0001-7800-3189
Tao Jiang https://orcid.org/0000-0002-7008-6351
Huimin Hu https://orcid.org/0000-0001-5712-3624

REFERENCES
1. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498. https://doi.org/10.1056/NEJMo a1402121.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1.
3. Bai H, Harmanci AS, Erson-Omay EZ, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet. 2016;48(1):59-66. https://doi.org/10.1038/ng.3457.
4. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193. https://doi.org/10.1126/science.1239947.
5. Mazor T, Pankov A, Johnson BE, et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell. 2015;28(3):307-317. https://doi.org/10.1016/j.ccell.2015.07.012.
6. Mazor T, Chesnelong C, Pankov A, et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci USA. 2017;114(40):10743-10748. https://doi.org/10.1073/pnas.1708914114.
7. Hu H, Mu Q, Bao Z, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018;175(6):1665-1678. https://doi.org/10.1016/j.cell.2018.09.038.
8. Hu H, Wang Z, Liu Y, et al. Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. Cancer Lett. 2015;357(2):566-574. https://doi.org/10.1016/j.canlet.2014.12.018.
9. Liu Y, Hu H, Wang K, et al. Multidimensional analysis of gene expression reveals TGFBI1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget. 2014;5(24):12593-12606. https://doi.org/10.18632/oncotarget.2518.
10. International Cancer Genome Consortium PedBrain Tumor Project. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22(11):1314-1320. https://doi.org/10.1038/nm.4204.
11. Xu D, Zhang Y. Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field. Proteins. 2012;80(7):1715-1735. https://doi.org/10.1002/prot.24065.
12. Xu D, Zhang Y. Toward optimal fragment generations for ab initio protein structure assembly. Proteins. 2013;81(2):229-239. https://doi.org/10.1002/prot.24179.
13. Garrett TPJ, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763-773.
14. Cohen-Katsenelson K, Wasserman T, Darlyuk-Saadon I, Rabner A, Glaser F, Aronheim A. Identification and analysis of a novel dimerization domain shared by various members of c-Jun N-terminal kinase (JNK) scaffold proteins. J Biol Chem. 2013;288(10):7294-7304. https://doi.org/10.1074/jbc.M112.422055.
15. Bao Z-S, Chen H-M, Yang M-Y, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24(11):1765-1773. https://doi.org/10.1101/gr.165126.113.
16. Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019;51(7):1113–1122. https://doi.org/10.1038/s41588-019-0423-x.
17. Jones S, Chen W-D, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105(11):4283-4288. https://doi.org/10.1073/pnas.0712345105.
18. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109–1113. https://doi.org/10.1038/nature09460.
19. van de Vijver MJ, He YD, van ’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2000;347(25):1999-2009. https://doi.org/10.1056/NEJMoa021967.
20. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49–54. https://doi.org/10.1038/ng1060.
21. Shan L, Lian F, Guo L, et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One. 2015;10(3):e0120422. https://doi.org/10.1371/journal.pone.0120422.
22. Arvey A, Herrmann A, Hsia CC, Le E, Freund Y, McGinnis W. Minimizing off-target signals in RNA fluorescent in situ hybridization. Nucleic Acids Res. 2010;38(10):e115. https://doi.org/10.1093/nar/gkq042.
23. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res. 2005;15(1):49–51. https://doi.org/10.1038/sj.cr.7290264.

24. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. https://doi.org/10.1038/nrc3205.

25. Basilico C, Hultberg A, Blanchetot C, et al. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest. 2014;124(7):3172–3186. https://doi.org/10.1172/JCI72316.

26. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6(1):75–84. https://doi.org/10.1016/j.ccr.2004.06.013.

27. Wickramasinghe D, Kong-Beltran M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle. 2005;4(5):683–685. https://doi.org/10.4161/cc.4.5.1688.

28. Yamanashi Y, Tezuka T, Yokoyama K. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment. J Biochem. 2012;151(4):353–359. https://doi.org/10.1093/jb/mvs013.

29. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134. https://doi.org/10.1016/j.cell.2010.06.011.

30. Hu H, Liu Y, Jiang T. Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis. Tumour Biol. 2015;36(3):1423–1428. https://doi.org/10.1007/s13277-015-3287-4.

31. Clémenson C, Chargari C, Liu W, et al. The MET/AXL/FGFR inhibitor S49076 impairs aurora B activity and improves the antitumor efficacy of radiotherapy. Mol Cancer Ther. 2017;16(10):2107–2119. https://doi.org/10.1158/1535-7163.MCT-17-0112.

32. Olwill SA, Joffroy C, Gille H, et al. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther. 2013;12(11):2459–2471. https://doi.org/10.1158/1535-7163.MCT-13-0318.

33. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005;11(12):4479–4486. https://doi.org/10.1158/1078-0432.CCR-05-0166.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Huang R, Liu Y, Wang K, et al. High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. CNS Neurosci Ther. 2021;27:617–628. https://doi.org/10.1111/cns.13627